INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29801, 13314, 'Acetylcysteine', 'Dehydration', 'Intravenous administration of acetylcysteine can cause fluid overload, potentially resulting in hyponatremia, seizure and death.  To avoid fluid overload, a diluted dose is recommended, especially in patients less than 40 kg and those requiring fluid restrictions (see dosage and administration recommended by manufacturers).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29802, 13328, 'Acetylcysteine', 'Dehydration', 'Intravenous administration of acetylcysteine can cause fluid overload, potentially resulting in hyponatremia, seizure and death.  To avoid fluid overload, a diluted dose is recommended, especially in patients less than 40 kg and those requiring fluid restrictions (see dosage and administration recommended by manufacturers).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29803, 19211, 'Acetylcysteine', 'Dehydration', 'Intravenous administration of acetylcysteine can cause fluid overload, potentially resulting in hyponatremia, seizure and death.  To avoid fluid overload, a diluted dose is recommended, especially in patients less than 40 kg and those requiring fluid restrictions (see dosage and administration recommended by manufacturers).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29804, 19212, 'Acetylcysteine', 'Dehydration', 'Intravenous administration of acetylcysteine can cause fluid overload, potentially resulting in hyponatremia, seizure and death.  To avoid fluid overload, a diluted dose is recommended, especially in patients less than 40 kg and those requiring fluid restrictions (see dosage and administration recommended by manufacturers).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29805, 20473, 'Acetylcysteine', 'Dehydration', 'Intravenous administration of acetylcysteine can cause fluid overload, potentially resulting in hyponatremia, seizure and death.  To avoid fluid overload, a diluted dose is recommended, especially in patients less than 40 kg and those requiring fluid restrictions (see dosage and administration recommended by manufacturers).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29806, 23063, 'Acetylcysteine', 'Dehydration', 'Intravenous administration of acetylcysteine can cause fluid overload, potentially resulting in hyponatremia, seizure and death.  To avoid fluid overload, a diluted dose is recommended, especially in patients less than 40 kg and those requiring fluid restrictions (see dosage and administration recommended by manufacturers).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29807, 23070, 'Acetylcysteine', 'Dehydration', 'Intravenous administration of acetylcysteine can cause fluid overload, potentially resulting in hyponatremia, seizure and death.  To avoid fluid overload, a diluted dose is recommended, especially in patients less than 40 kg and those requiring fluid restrictions (see dosage and administration recommended by manufacturers).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29808, 26326, 'Acetylcysteine', 'Dehydration', 'Intravenous administration of acetylcysteine can cause fluid overload, potentially resulting in hyponatremia, seizure and death.  To avoid fluid overload, a diluted dose is recommended, especially in patients less than 40 kg and those requiring fluid restrictions (see dosage and administration recommended by manufacturers).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29809, 26327, 'Acetylcysteine', 'Dehydration', 'Intravenous administration of acetylcysteine can cause fluid overload, potentially resulting in hyponatremia, seizure and death.  To avoid fluid overload, a diluted dose is recommended, especially in patients less than 40 kg and those requiring fluid restrictions (see dosage and administration recommended by manufacturers).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29810, 27273, 'Acetylcysteine', 'Dehydration', 'Intravenous administration of acetylcysteine can cause fluid overload, potentially resulting in hyponatremia, seizure and death.  To avoid fluid overload, a diluted dose is recommended, especially in patients less than 40 kg and those requiring fluid restrictions (see dosage and administration recommended by manufacturers).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29811, 27676, 'Acetylcysteine', 'Dehydration', 'Intravenous administration of acetylcysteine can cause fluid overload, potentially resulting in hyponatremia, seizure and death.  To avoid fluid overload, a diluted dose is recommended, especially in patients less than 40 kg and those requiring fluid restrictions (see dosage and administration recommended by manufacturers).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29812, 30073, 'Acetylcysteine', 'Dehydration', 'Intravenous administration of acetylcysteine can cause fluid overload, potentially resulting in hyponatremia, seizure and death.  To avoid fluid overload, a diluted dose is recommended, especially in patients less than 40 kg and those requiring fluid restrictions (see dosage and administration recommended by manufacturers).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29813, 30074, 'Acetylcysteine', 'Dehydration', 'Intravenous administration of acetylcysteine can cause fluid overload, potentially resulting in hyponatremia, seizure and death.  To avoid fluid overload, a diluted dose is recommended, especially in patients less than 40 kg and those requiring fluid restrictions (see dosage and administration recommended by manufacturers).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29814, 30358, 'Acetylcysteine', 'Dehydration', 'Intravenous administration of acetylcysteine can cause fluid overload, potentially resulting in hyponatremia, seizure and death.  To avoid fluid overload, a diluted dose is recommended, especially in patients less than 40 kg and those requiring fluid restrictions (see dosage and administration recommended by manufacturers).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29815, 30588, 'Acetylcysteine', 'Dehydration', 'Intravenous administration of acetylcysteine can cause fluid overload, potentially resulting in hyponatremia, seizure and death.  To avoid fluid overload, a diluted dose is recommended, especially in patients less than 40 kg and those requiring fluid restrictions (see dosage and administration recommended by manufacturers).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29816, 30589, 'Acetylcysteine', 'Dehydration', 'Intravenous administration of acetylcysteine can cause fluid overload, potentially resulting in hyponatremia, seizure and death.  To avoid fluid overload, a diluted dose is recommended, especially in patients less than 40 kg and those requiring fluid restrictions (see dosage and administration recommended by manufacturers).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29817, 31259, 'Acetylcysteine', 'Dehydration', 'Intravenous administration of acetylcysteine can cause fluid overload, potentially resulting in hyponatremia, seizure and death.  To avoid fluid overload, a diluted dose is recommended, especially in patients less than 40 kg and those requiring fluid restrictions (see dosage and administration recommended by manufacturers).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29818, 32105, 'Acetylcysteine', 'Dehydration', 'Intravenous administration of acetylcysteine can cause fluid overload, potentially resulting in hyponatremia, seizure and death.  To avoid fluid overload, a diluted dose is recommended, especially in patients less than 40 kg and those requiring fluid restrictions (see dosage and administration recommended by manufacturers).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29819, 32683, 'Acetylcysteine', 'Dehydration', 'Intravenous administration of acetylcysteine can cause fluid overload, potentially resulting in hyponatremia, seizure and death.  To avoid fluid overload, a diluted dose is recommended, especially in patients less than 40 kg and those requiring fluid restrictions (see dosage and administration recommended by manufacturers).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29820, 37, 'Acetylcysteine', 'Gastrointestinal Hemorrhage', 'The use of acetylcysteine may worsen vomiting.  Patients with peptic ulcer disease should be evaluated for the risk of gastrointestinal hemorrhage.  In the presence of gastric hemorrhage, the decision to administer this agent should take into consideration the benefits versus the risks to an individual patient.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29821, 39, 'Acetylcysteine', 'Gastrointestinal Hemorrhage', 'The use of acetylcysteine may worsen vomiting.  Patients with peptic ulcer disease should be evaluated for the risk of gastrointestinal hemorrhage.  In the presence of gastric hemorrhage, the decision to administer this agent should take into consideration the benefits versus the risks to an individual patient.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29822, 49, 'Acetylcysteine', 'Gastrointestinal Hemorrhage', 'The use of acetylcysteine may worsen vomiting.  Patients with peptic ulcer disease should be evaluated for the risk of gastrointestinal hemorrhage.  In the presence of gastric hemorrhage, the decision to administer this agent should take into consideration the benefits versus the risks to an individual patient.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29823, 1642, 'Acetylcysteine', 'Gastrointestinal Hemorrhage', 'The use of acetylcysteine may worsen vomiting.  Patients with peptic ulcer disease should be evaluated for the risk of gastrointestinal hemorrhage.  In the presence of gastric hemorrhage, the decision to administer this agent should take into consideration the benefits versus the risks to an individual patient.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29824, 1772, 'Acetylcysteine', 'Gastrointestinal Hemorrhage', 'The use of acetylcysteine may worsen vomiting.  Patients with peptic ulcer disease should be evaluated for the risk of gastrointestinal hemorrhage.  In the presence of gastric hemorrhage, the decision to administer this agent should take into consideration the benefits versus the risks to an individual patient.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29825, 3383, 'Acetylcysteine', 'Gastrointestinal Hemorrhage', 'The use of acetylcysteine may worsen vomiting.  Patients with peptic ulcer disease should be evaluated for the risk of gastrointestinal hemorrhage.  In the presence of gastric hemorrhage, the decision to administer this agent should take into consideration the benefits versus the risks to an individual patient.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29826, 5480, 'Acetylcysteine', 'Gastrointestinal Hemorrhage', 'The use of acetylcysteine may worsen vomiting.  Patients with peptic ulcer disease should be evaluated for the risk of gastrointestinal hemorrhage.  In the presence of gastric hemorrhage, the decision to administer this agent should take into consideration the benefits versus the risks to an individual patient.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29827, 5545, 'Acetylcysteine', 'Gastrointestinal Hemorrhage', 'The use of acetylcysteine may worsen vomiting.  Patients with peptic ulcer disease should be evaluated for the risk of gastrointestinal hemorrhage.  In the presence of gastric hemorrhage, the decision to administer this agent should take into consideration the benefits versus the risks to an individual patient.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29828, 12631, 'Acetylcysteine', 'Gastrointestinal Hemorrhage', 'The use of acetylcysteine may worsen vomiting.  Patients with peptic ulcer disease should be evaluated for the risk of gastrointestinal hemorrhage.  In the presence of gastric hemorrhage, the decision to administer this agent should take into consideration the benefits versus the risks to an individual patient.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29829, 13314, 'Acetylcysteine', 'Gastrointestinal Hemorrhage', 'The use of acetylcysteine may worsen vomiting.  Patients with peptic ulcer disease should be evaluated for the risk of gastrointestinal hemorrhage.  In the presence of gastric hemorrhage, the decision to administer this agent should take into consideration the benefits versus the risks to an individual patient.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29830, 13328, 'Acetylcysteine', 'Gastrointestinal Hemorrhage', 'The use of acetylcysteine may worsen vomiting.  Patients with peptic ulcer disease should be evaluated for the risk of gastrointestinal hemorrhage.  In the presence of gastric hemorrhage, the decision to administer this agent should take into consideration the benefits versus the risks to an individual patient.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29831, 19211, 'Acetylcysteine', 'Gastrointestinal Hemorrhage', 'The use of acetylcysteine may worsen vomiting.  Patients with peptic ulcer disease should be evaluated for the risk of gastrointestinal hemorrhage.  In the presence of gastric hemorrhage, the decision to administer this agent should take into consideration the benefits versus the risks to an individual patient.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29832, 19212, 'Acetylcysteine', 'Gastrointestinal Hemorrhage', 'The use of acetylcysteine may worsen vomiting.  Patients with peptic ulcer disease should be evaluated for the risk of gastrointestinal hemorrhage.  In the presence of gastric hemorrhage, the decision to administer this agent should take into consideration the benefits versus the risks to an individual patient.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29833, 20473, 'Acetylcysteine', 'Gastrointestinal Hemorrhage', 'The use of acetylcysteine may worsen vomiting.  Patients with peptic ulcer disease should be evaluated for the risk of gastrointestinal hemorrhage.  In the presence of gastric hemorrhage, the decision to administer this agent should take into consideration the benefits versus the risks to an individual patient.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29834, 23063, 'Acetylcysteine', 'Gastrointestinal Hemorrhage', 'The use of acetylcysteine may worsen vomiting.  Patients with peptic ulcer disease should be evaluated for the risk of gastrointestinal hemorrhage.  In the presence of gastric hemorrhage, the decision to administer this agent should take into consideration the benefits versus the risks to an individual patient.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29835, 23070, 'Acetylcysteine', 'Gastrointestinal Hemorrhage', 'The use of acetylcysteine may worsen vomiting.  Patients with peptic ulcer disease should be evaluated for the risk of gastrointestinal hemorrhage.  In the presence of gastric hemorrhage, the decision to administer this agent should take into consideration the benefits versus the risks to an individual patient.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29836, 26326, 'Acetylcysteine', 'Gastrointestinal Hemorrhage', 'The use of acetylcysteine may worsen vomiting.  Patients with peptic ulcer disease should be evaluated for the risk of gastrointestinal hemorrhage.  In the presence of gastric hemorrhage, the decision to administer this agent should take into consideration the benefits versus the risks to an individual patient.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29837, 26327, 'Acetylcysteine', 'Gastrointestinal Hemorrhage', 'The use of acetylcysteine may worsen vomiting.  Patients with peptic ulcer disease should be evaluated for the risk of gastrointestinal hemorrhage.  In the presence of gastric hemorrhage, the decision to administer this agent should take into consideration the benefits versus the risks to an individual patient.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29838, 27273, 'Acetylcysteine', 'Gastrointestinal Hemorrhage', 'The use of acetylcysteine may worsen vomiting.  Patients with peptic ulcer disease should be evaluated for the risk of gastrointestinal hemorrhage.  In the presence of gastric hemorrhage, the decision to administer this agent should take into consideration the benefits versus the risks to an individual patient.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29839, 27676, 'Acetylcysteine', 'Gastrointestinal Hemorrhage', 'The use of acetylcysteine may worsen vomiting.  Patients with peptic ulcer disease should be evaluated for the risk of gastrointestinal hemorrhage.  In the presence of gastric hemorrhage, the decision to administer this agent should take into consideration the benefits versus the risks to an individual patient.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29840, 30073, 'Acetylcysteine', 'Gastrointestinal Hemorrhage', 'The use of acetylcysteine may worsen vomiting.  Patients with peptic ulcer disease should be evaluated for the risk of gastrointestinal hemorrhage.  In the presence of gastric hemorrhage, the decision to administer this agent should take into consideration the benefits versus the risks to an individual patient.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29841, 30074, 'Acetylcysteine', 'Gastrointestinal Hemorrhage', 'The use of acetylcysteine may worsen vomiting.  Patients with peptic ulcer disease should be evaluated for the risk of gastrointestinal hemorrhage.  In the presence of gastric hemorrhage, the decision to administer this agent should take into consideration the benefits versus the risks to an individual patient.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29842, 30358, 'Acetylcysteine', 'Gastrointestinal Hemorrhage', 'The use of acetylcysteine may worsen vomiting.  Patients with peptic ulcer disease should be evaluated for the risk of gastrointestinal hemorrhage.  In the presence of gastric hemorrhage, the decision to administer this agent should take into consideration the benefits versus the risks to an individual patient.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29843, 30588, 'Acetylcysteine', 'Gastrointestinal Hemorrhage', 'The use of acetylcysteine may worsen vomiting.  Patients with peptic ulcer disease should be evaluated for the risk of gastrointestinal hemorrhage.  In the presence of gastric hemorrhage, the decision to administer this agent should take into consideration the benefits versus the risks to an individual patient.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29844, 30589, 'Acetylcysteine', 'Gastrointestinal Hemorrhage', 'The use of acetylcysteine may worsen vomiting.  Patients with peptic ulcer disease should be evaluated for the risk of gastrointestinal hemorrhage.  In the presence of gastric hemorrhage, the decision to administer this agent should take into consideration the benefits versus the risks to an individual patient.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29845, 31259, 'Acetylcysteine', 'Gastrointestinal Hemorrhage', 'The use of acetylcysteine may worsen vomiting.  Patients with peptic ulcer disease should be evaluated for the risk of gastrointestinal hemorrhage.  In the presence of gastric hemorrhage, the decision to administer this agent should take into consideration the benefits versus the risks to an individual patient.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29846, 32105, 'Acetylcysteine', 'Gastrointestinal Hemorrhage', 'The use of acetylcysteine may worsen vomiting.  Patients with peptic ulcer disease should be evaluated for the risk of gastrointestinal hemorrhage.  In the presence of gastric hemorrhage, the decision to administer this agent should take into consideration the benefits versus the risks to an individual patient.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29847, 32683, 'Acetylcysteine', 'Gastrointestinal Hemorrhage', 'The use of acetylcysteine may worsen vomiting.  Patients with peptic ulcer disease should be evaluated for the risk of gastrointestinal hemorrhage.  In the presence of gastric hemorrhage, the decision to administer this agent should take into consideration the benefits versus the risks to an individual patient.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29848, 0, 'Ulobetasol (topical)', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29849, 0, 'Ulobetasol (topical)', 'Diaper Rash', 'Topical corticosteroids, especially the potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol), are generally not recommended for use in the treatment of diaper rash.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are usually at the greatest risk for systemic toxicity such as adrenal suppression, Cushing''s syndrome and intracranial hypertension because of their larger skin surface to body mass ratios.  If topical corticosteroids are necessary to treat diaper rash, medium- to low-potency agents should preferably be used, and parents should be advised not to put tight-fitting diapers or plastic pants over the rash, since occlusion of treated area may increase percutaneous drug absorption.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29850, 0, 'Ulobetasol (topical)', 'Adrenocortical Hyperfunction', 'The use of topical corticosteroids may precipitate or aggravate conditions of hyperadrenocorticism.  Systemic absorption of these agents can produce reversible hypothalamic-pituitary-adrenal axis suppression.  Systemic absorption, depends on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Patients with an altered skin barrier or liver failure are also at increased risk.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during topical corticosteroid therapy may indicate excessive use.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29851, 0, 'Ulobetasol (topical)', 'Infections', 'Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Clinically significant local as well as systemic immunosuppressant and anti-inflammatory effects may occur, which can cause or exacerbate an infection.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Therapy with topical corticosteroids should be administered cautiously in patients with latent or active infections, particularly if a potent agent is used on a large area for prolonged periods or if occlusive dressings are used.  Effective antimicrobial therapy or other appropriate treatment should be instituted to treat the infection.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Occlusive dressings should not be used in patients with skin infection.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29852, 0, 'Ulobetasol (topical)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure, especially when potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) are used in the periorbital area.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29853, 14201, 'Umeclidinium', 'Milk Hypersensitivity', 'Some inhaled anticholinergic bronchodilators such as aclidinium and umeclidinium are contraindicated in patients with severe hypersensitivity to milk proteins.  There have been reports of anaphylactic reactions on these patients after inhalation of other powder products containing lactose, therefore patients with severe milk protein allergy should not use these products.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29854, 14201, 'Umeclidinium', 'Anticholinergic Syndrome', 'Aclidinium, ipratropium, umeclidinium, and tiotropium are anticholinergic agents.  Although systemic effects are uncommon due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa, worsening of urinary retention or angle-closure glaucoma has been reported.  Increased intraocular pressure and precipitation or exacerbation of angle-closure glaucoma may also occur due to inadvertent contact of the eye with aerosolized or nebulized drug.  Accordingly, therapy with quaternary ammonium compounds should be administered cautiously in patients with urinary retention/obstruction or angle-closure glaucoma.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation or use of a mouthpiece rather than face mask during nebulization.  Patients should be advised to contact their physician if they experience urinary difficulty (especially in patients with prostatic hyperplasia or bladder neck obstruction); or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29855, 14201, 'Umeclidinium', 'Liver Failure', 'Patients with moderate hepatic impairment showed no relevant increases in Cmax or AUC when using umeclidinium, when compared with healthy subjects.  However, studies have not been performed in patients with severe hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29856, 3845, 'Urea', 'Dehydration', 'The use of osmotic diuretics is contraindicated in patients with anuria, severe dehydration, pulmonary edema, or severe cardiac decompensation.  An increase in the tonicity of the blood may occur in these patients that could exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29857, 4664, 'Urea', 'Dehydration', 'The use of osmotic diuretics is contraindicated in patients with anuria, severe dehydration, pulmonary edema, or severe cardiac decompensation.  An increase in the tonicity of the blood may occur in these patients that could exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29858, 11955, 'Urea', 'Dehydration', 'The use of osmotic diuretics is contraindicated in patients with anuria, severe dehydration, pulmonary edema, or severe cardiac decompensation.  An increase in the tonicity of the blood may occur in these patients that could exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29859, 29577, 'Urea', 'Dehydration', 'The use of osmotic diuretics is contraindicated in patients with anuria, severe dehydration, pulmonary edema, or severe cardiac decompensation.  An increase in the tonicity of the blood may occur in these patients that could exacerbate these conditions.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29860, 3998, 'Upadacitinib', 'Cardiovascular Diseases', 'In a major safety study of a Janus kinase (JAK) inhibitor, tofacitinib, in rheumatoid arthritis patients 50 years and older with at least 1 cardiovascular risk factor, higher rates of all-cause mortality (including sudden cardiovascular death) and major adverse cardiovascular events (MACE) (defined as cardiovascular death, myocardial infarction, and stroke) were observed with the JAK inhibitor when compared with tumor necrosis factor (TNF) blockers; patients who are current or past smokers are at additional increased risk.  Based on a shared mechanism of action, this risk should be considered for other JAK inhibitors, including baricitinib, upadacitinib, ruxolitinib, fedratinib, and pacritinib.  Before starting or continuing therapy, the benefits and risks for the individual patient should be considered, especially in patients with other cardiovascular risk factors and patients who are current or past smokers.  Patients should be informed about the symptoms of serious cardiovascular events and what to do if they occur.  Tofacitinib, baricitinib, and upadacitinib are indicated for patients with inadequate response or intolerance to 1 or more TNF blockers, but should be discontinued in patients who have experienced a myocardial infarction or stroke.  The dosage recommended for tofacitinib should not be exceeded; for the treatment of ulcerative colitis, tofacitinib should be used at the lowest effective dose and for the shortest duration needed to achieve and/or maintain therapeutic response.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29861, 31916, 'Upadacitinib', 'Cardiovascular Diseases', 'In a major safety study of a Janus kinase (JAK) inhibitor, tofacitinib, in rheumatoid arthritis patients 50 years and older with at least 1 cardiovascular risk factor, higher rates of all-cause mortality (including sudden cardiovascular death) and major adverse cardiovascular events (MACE) (defined as cardiovascular death, myocardial infarction, and stroke) were observed with the JAK inhibitor when compared with tumor necrosis factor (TNF) blockers; patients who are current or past smokers are at additional increased risk.  Based on a shared mechanism of action, this risk should be considered for other JAK inhibitors, including baricitinib, upadacitinib, ruxolitinib, fedratinib, and pacritinib.  Before starting or continuing therapy, the benefits and risks for the individual patient should be considered, especially in patients with other cardiovascular risk factors and patients who are current or past smokers.  Patients should be informed about the symptoms of serious cardiovascular events and what to do if they occur.  Tofacitinib, baricitinib, and upadacitinib are indicated for patients with inadequate response or intolerance to 1 or more TNF blockers, but should be discontinued in patients who have experienced a myocardial infarction or stroke.  The dosage recommended for tofacitinib should not be exceeded; for the treatment of ulcerative colitis, tofacitinib should be used at the lowest effective dose and for the shortest duration needed to achieve and/or maintain therapeutic response.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29862, 3998, 'Upadacitinib', 'Neoplasms', 'Malignancies (including lymphomas and solid tumors) have been reported in patients treated with tofacitinib and other Janus kinase (JAK) inhibitors used to treat inflammatory conditions; lymphomas and other malignancies have been seen in patients treated with baricitinib or upadacitinib.  Patients who are current or past smokers are at additional increased risk of malignancies.  Based on a shared mechanism of action, this risk should be considered for other JAK inhibitors, including ruxolitinib, pacritinib, and fedratinib.  Before starting or continuing therapy, the benefits and risks for the individual patient should be considered, especially in patients with a known malignancy (other than successfully treated nonmelanoma skin cancer), patients who develop a malignancy during therapy, and patients who are current or past smokers.  Periodic skin examination is recommended for patients who are at increased risk for skin cancer.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29863, 31916, 'Upadacitinib', 'Neoplasms', 'Malignancies (including lymphomas and solid tumors) have been reported in patients treated with tofacitinib and other Janus kinase (JAK) inhibitors used to treat inflammatory conditions; lymphomas and other malignancies have been seen in patients treated with baricitinib or upadacitinib.  Patients who are current or past smokers are at additional increased risk of malignancies.  Based on a shared mechanism of action, this risk should be considered for other JAK inhibitors, including ruxolitinib, pacritinib, and fedratinib.  Before starting or continuing therapy, the benefits and risks for the individual patient should be considered, especially in patients with a known malignancy (other than successfully treated nonmelanoma skin cancer), patients who develop a malignancy during therapy, and patients who are current or past smokers.  Periodic skin examination is recommended for patients who are at increased risk for skin cancer.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29864, 3998, 'Upadacitinib', 'Thrombosis', 'Thrombosis (including deep venous thrombosis, pulmonary embolism, and arterial thrombosis) has occurred in patients treated for inflammatory conditions with Janus kinase (JAK) inhibitors, including baricitinib, tofacitinib, and upadacitinib; many of these adverse events were serious and some resulted in death.  Based on a shared mechanism of action, this risk should be considered for other JAK inhibitors, including ruxolitinib, fedratinib, and pacritinib.  Baricitinib, pacritinib, tofacitinib, and upadacitinib should be avoided in patients who may be at increased risk of thrombosis; for the treatment of ulcerative colitis, tofacitinib should be used at the lowest effective dose and for the shortest duration needed to achieve/maintain therapeutic response.  If symptoms of thrombosis occur, baricitinib, pacritinib, tofacitinib, and upadacitinib should be discontinued and patients should be evaluated promptly and treated appropriately.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29865, 31916, 'Upadacitinib', 'Thrombosis', 'Thrombosis (including deep venous thrombosis, pulmonary embolism, and arterial thrombosis) has occurred in patients treated for inflammatory conditions with Janus kinase (JAK) inhibitors, including baricitinib, tofacitinib, and upadacitinib; many of these adverse events were serious and some resulted in death.  Based on a shared mechanism of action, this risk should be considered for other JAK inhibitors, including ruxolitinib, fedratinib, and pacritinib.  Baricitinib, pacritinib, tofacitinib, and upadacitinib should be avoided in patients who may be at increased risk of thrombosis; for the treatment of ulcerative colitis, tofacitinib should be used at the lowest effective dose and for the shortest duration needed to achieve/maintain therapeutic response.  If symptoms of thrombosis occur, baricitinib, pacritinib, tofacitinib, and upadacitinib should be discontinued and patients should be evaluated promptly and treated appropriately.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29866, 3998, 'Upadacitinib', 'Infections', 'Serious and sometimes fatal infections, including opportunistic and reactivation of infections have been reported in patients receiving upadacitinib treatment.  It is recommended to avoid the use of upadacitinib in patients with an active, serious infection, including localized infections.  Closely monitor patients for the development of signs and symptoms of infection during and after treatment with upadacitinib.  Interrupt therapy if a patient develops a new infection or an opportunistic infection and appropriate antimicrobial therapy should be initiated.  Treatment with upadacitinib may be resumed once the infection is controlled.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29867, 31916, 'Upadacitinib', 'Infections', 'Serious and sometimes fatal infections, including opportunistic and reactivation of infections have been reported in patients receiving upadacitinib treatment.  It is recommended to avoid the use of upadacitinib in patients with an active, serious infection, including localized infections.  Closely monitor patients for the development of signs and symptoms of infection during and after treatment with upadacitinib.  Interrupt therapy if a patient develops a new infection or an opportunistic infection and appropriate antimicrobial therapy should be initiated.  Treatment with upadacitinib may be resumed once the infection is controlled.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29868, 3998, 'Upadacitinib', 'Pancytopenia', 'The use of upadacitinib is associated with an increase incidence of neutropenia, lymphopenia, and anemia.  Avoid initiation or interrupt treatment with upadacitinib in patients with low neutrophil counts (i.e., ANC less than 1000 cells/mm3), lymphocyte counts (i.e., less than 500 cells/mm3) and low hemoglobin levels (i.e., less than 8 g/dL).  It is recommended to evaluate patients for abnormal blood cell counts at baseline and thereafter according to routine patient management.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29869, 31916, 'Upadacitinib', 'Pancytopenia', 'The use of upadacitinib is associated with an increase incidence of neutropenia, lymphopenia, and anemia.  Avoid initiation or interrupt treatment with upadacitinib in patients with low neutrophil counts (i.e., ANC less than 1000 cells/mm3), lymphocyte counts (i.e., less than 500 cells/mm3) and low hemoglobin levels (i.e., less than 8 g/dL).  It is recommended to evaluate patients for abnormal blood cell counts at baseline and thereafter according to routine patient management.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29870, 3998, 'Upadacitinib', 'Peptic Ulcer Perforation', 'Gastrointestinal perforation has been reported with the use of upadacitinib.  This agent should be used with caution in patients who may be at increased risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis or taking NSAIDs).  It is recommended to monitor for new onset abdominal symptoms for early identification of gastrointestinal perforation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29871, 31916, 'Upadacitinib', 'Peptic Ulcer Perforation', 'Gastrointestinal perforation has been reported with the use of upadacitinib.  This agent should be used with caution in patients who may be at increased risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis or taking NSAIDs).  It is recommended to monitor for new onset abdominal symptoms for early identification of gastrointestinal perforation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29872, 3998, 'Upadacitinib', 'Hepatic Insufficiency', 'The use of upadacitinib is not recommended in patients with severe hepatic impairment.  No dose adjustment is required in patients with mild or moderate hepatic impairment.  Treatment with upadacitinib is associated with increased incidence of liver enzyme elevation.  Evaluate baseline liver function and thereafter according to routine patient management.  Treatment should be interrupted if drug-induced liver injury is suspected.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29873, 31916, 'Upadacitinib', 'Hepatic Insufficiency', 'The use of upadacitinib is not recommended in patients with severe hepatic impairment.  No dose adjustment is required in patients with mild or moderate hepatic impairment.  Treatment with upadacitinib is associated with increased incidence of liver enzyme elevation.  Evaluate baseline liver function and thereafter according to routine patient management.  Treatment should be interrupted if drug-induced liver injury is suspected.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29874, 3998, 'Upadacitinib', 'Hyperlipidemias', 'Treatment with upadacitinib is associated with increases in lipid parameters, including total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol.  Care should be exercised when using this agent in patients with hyperlipidemia.  It is recommended to monitor patients after initiation of treatment, and thereafter according to the clinical guidelines and to manage patients accordingly.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29875, 31916, 'Upadacitinib', 'Hyperlipidemias', 'Treatment with upadacitinib is associated with increases in lipid parameters, including total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol.  Care should be exercised when using this agent in patients with hyperlipidemia.  It is recommended to monitor patients after initiation of treatment, and thereafter according to the clinical guidelines and to manage patients accordingly.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29876, 19763, 'Ulipristal', 'Hepatic Insufficiency', 'No studies have been conducted to evaluate the effect of hepatic disease on the disposition of ulipristal.  Caution is recommended when using this agent in patients with liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29877, 23744, 'Ulipristal', 'Hepatic Insufficiency', 'No studies have been conducted to evaluate the effect of hepatic disease on the disposition of ulipristal.  Caution is recommended when using this agent in patients with liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29878, 23745, 'Ulipristal', 'Hepatic Insufficiency', 'No studies have been conducted to evaluate the effect of hepatic disease on the disposition of ulipristal.  Caution is recommended when using this agent in patients with liver disease.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29879, 19763, 'Ulipristal', 'Kidney Diseases', 'No studies have been conducted to evaluate the effect of renal disease on the disposition of ulipristal.  Caution is recommended when using this agent in patients with renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29880, 23744, 'Ulipristal', 'Kidney Diseases', 'No studies have been conducted to evaluate the effect of renal disease on the disposition of ulipristal.  Caution is recommended when using this agent in patients with renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29881, 23745, 'Ulipristal', 'Kidney Diseases', 'No studies have been conducted to evaluate the effect of renal disease on the disposition of ulipristal.  Caution is recommended when using this agent in patients with renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29882, 0, 'Benzylpenicillin (potassium)', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29883, 0, 'Benzylpenicillin (potassium)', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29884, 0, 'Benzylpenicillin (potassium)', 'Hyperkalemia', 'Each million units of penicillin G potassium contains approximately 6.8 milligrams of sodium (0.3 mEq) and 65.6 milligrams of potassium (1.68 mEq) and may cause serious and even fatal electrolyte disturbances, i.e., hyperkalemia, when given intravenously in large doses.  Clinical monitoring of electrolytes is recommended if these agents are used.  Care should be exercised when using this agent in patients with electrolytes abnormalities.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29885, 0, 'Benzylpenicillin (potassium)', 'Asthma', 'Penicillin products should be used with caution in individuals with histories of significant allergies and/or asthma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29886, 0, 'Benzylpenicillin (potassium)', 'Diseases requiring hemodialysis', 'Penicillin antibiotics (except for agents in the penicillinase-resistant class) are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29887, 15466, 'Urofollitropin', 'Adrenal Insufficiency', 'The use of follicle stimulating hormone (FSH) is contraindicated in patients with uncontrolled adrenal dysfunction.  Uncontrolled adrenal dysfunction may involve the pituitary gland and be associated with a tumor or other dysfunction.  Administration of FSH may exacerbate the condition.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29888, 19367, 'Urofollitropin', 'Adrenal Insufficiency', 'The use of follicle stimulating hormone (FSH) is contraindicated in patients with uncontrolled adrenal dysfunction.  Uncontrolled adrenal dysfunction may involve the pituitary gland and be associated with a tumor or other dysfunction.  Administration of FSH may exacerbate the condition.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29889, 19368, 'Urofollitropin', 'Adrenal Insufficiency', 'The use of follicle stimulating hormone (FSH) is contraindicated in patients with uncontrolled adrenal dysfunction.  Uncontrolled adrenal dysfunction may involve the pituitary gland and be associated with a tumor or other dysfunction.  Administration of FSH may exacerbate the condition.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29890, 22671, 'Urofollitropin', 'Adrenal Insufficiency', 'The use of follicle stimulating hormone (FSH) is contraindicated in patients with uncontrolled adrenal dysfunction.  Uncontrolled adrenal dysfunction may involve the pituitary gland and be associated with a tumor or other dysfunction.  Administration of FSH may exacerbate the condition.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29891, 15466, 'Urofollitropin', 'Hypothyroidism', 'The use of follicle stimulating hormone (FSH) is contraindicated in patients with uncontrolled thyroid dysfunction.  FSH is composed of both an alpha and beta subunit.  The amino acid sequence of the alpha subunit of FSH is identical to that of TSH.  Therefore, FSH may have weak TSH receptor- binding and activation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29892, 19367, 'Urofollitropin', 'Hypothyroidism', 'The use of follicle stimulating hormone (FSH) is contraindicated in patients with uncontrolled thyroid dysfunction.  FSH is composed of both an alpha and beta subunit.  The amino acid sequence of the alpha subunit of FSH is identical to that of TSH.  Therefore, FSH may have weak TSH receptor- binding and activation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29893, 19368, 'Urofollitropin', 'Hypothyroidism', 'The use of follicle stimulating hormone (FSH) is contraindicated in patients with uncontrolled thyroid dysfunction.  FSH is composed of both an alpha and beta subunit.  The amino acid sequence of the alpha subunit of FSH is identical to that of TSH.  Therefore, FSH may have weak TSH receptor- binding and activation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29894, 22671, 'Urofollitropin', 'Hypothyroidism', 'The use of follicle stimulating hormone (FSH) is contraindicated in patients with uncontrolled thyroid dysfunction.  FSH is composed of both an alpha and beta subunit.  The amino acid sequence of the alpha subunit of FSH is identical to that of TSH.  Therefore, FSH may have weak TSH receptor- binding and activation.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29895, 15466, 'Urofollitropin', 'Neoplasms', 'The use of follicle stimulating hormone is contraindicated in patients with sex hormone-dependent tumors of the reproductive tract and accessory organs (ovary, breast, uterus) and in patients with pituitary tumors.  FSH is required for normal sex hormone production, which may be detrimental in these patients.  Patients in later reproductive life have a greater predisposition to endometrial carcinoma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29896, 19367, 'Urofollitropin', 'Neoplasms', 'The use of follicle stimulating hormone is contraindicated in patients with sex hormone-dependent tumors of the reproductive tract and accessory organs (ovary, breast, uterus) and in patients with pituitary tumors.  FSH is required for normal sex hormone production, which may be detrimental in these patients.  Patients in later reproductive life have a greater predisposition to endometrial carcinoma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29897, 19368, 'Urofollitropin', 'Neoplasms', 'The use of follicle stimulating hormone is contraindicated in patients with sex hormone-dependent tumors of the reproductive tract and accessory organs (ovary, breast, uterus) and in patients with pituitary tumors.  FSH is required for normal sex hormone production, which may be detrimental in these patients.  Patients in later reproductive life have a greater predisposition to endometrial carcinoma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29898, 22671, 'Urofollitropin', 'Neoplasms', 'The use of follicle stimulating hormone is contraindicated in patients with sex hormone-dependent tumors of the reproductive tract and accessory organs (ovary, breast, uterus) and in patients with pituitary tumors.  FSH is required for normal sex hormone production, which may be detrimental in these patients.  Patients in later reproductive life have a greater predisposition to endometrial carcinoma.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29899, 15466, 'Urofollitropin', 'Thromboembolism', 'Thromboembolic events, including venous thrombophlebitis, pulmonary embolism, pulmonary infarction, cerebrovascular occlusion (stroke), and arterial occlusion resulting in loss of limb, have been reported during administration of gonadotropin therapy, both in association with and independent of the Ovarian Hyperstimulation Syndrome.  Therapy with gonadotropins should be administered cautiously to patients with or predisposed to thromboembolism.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (29900, 19367, 'Urofollitropin', 'Thromboembolism', 'Thromboembolic events, including venous thrombophlebitis, pulmonary embolism, pulmonary infarction, cerebrovascular occlusion (stroke), and arterial occlusion resulting in loss of limb, have been reported during administration of gonadotropin therapy, both in association with and independent of the Ovarian Hyperstimulation Syndrome.  Therapy with gonadotropins should be administered cautiously to patients with or predisposed to thromboembolism.', '3', '', 'DDInter', 0);
